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The authors want to alert readers to the following errors in regard to Figure 3.

1.  In panels A (mTSS) and B (ES) for the RA-BEGIN graphs, the symbol (‡) indicating the significance level for the comparison between the baricitinib 4-mg and baricitinib 4-mg plus MTX treatment groups (denoting p≤0.05) should be over the 1 year time point, not the 2 year time point in both graphs.

2.  In panel A (mTSS) for RA-BEAM, for the adalimumab versus placebo comparison at 2 years, the significance should have been shown as ++ (p≤0.01) and not +++ (p≤0.001).

3.  In the Results text, p.8, line 12 (relating to Figure 3, panel A) '...baricitinib treatment groups (0.21±0.01...' should read: '...baricitinib treatment groups (0.21±0.10...'
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